Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel
NASDAQ:SLXN

Silexion Therapeutics Earnings Date & Estimates

Silexion Therapeutics logo
$0.18 0.00 (-0.57%)
As of 03:44 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Silexion Therapeutics is estimated to report earnings on Wednesday, November 11, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Silexion Therapeutics

Silexion Therapeutics is expected to post earnings of -$9.10 per share. In the same quarter a year earlier Silexion Therapeutics reported -$28.80 per share. Silexion Therapeutics last reported on August 15, 2026, posting -$5.17 per share and beating the -$21.20 consensus estimate. Silexion Therapeutics has beaten the consensus EPS estimate in 3 of its last 4 quarters.

Consensus Estimates

Consensus EPS
-$9.10
Prior-Year EPS
-$28.80

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$5.17 (Beat by +$16.03)
EPS Beat Rate
3 of last 4 quarters

Prepare for the Earnings Call

Silexion Therapeutics Earnings FAQ

Silexion Therapeutics (NASDAQ:SLXN) is estimated to report earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Silexion Therapeutics to post earnings of -$9.10 per share for the quarter.

Silexion Therapeutics Earnings Headlines

Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Large Growth in Short Interest
October 11 at 9:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31108145
Silexion Therapeutics Corp Ord Stock Short Interest Rises to 91.58%
October 10, 2026  |  quiverquant.comQ
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
October 14 at 1:00 AM  |  Awesomely (Ad)
Silexion Therapeutics consensus price target decreased by 91.67% to $5.10
October 1, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/silexion-therapeutics-consensus-price-target-decreased-by-91-67-to-5-10/ar-AA2dnrtj
Silexion Therapeutics begins phase 2/3 SIL204 trial with first patient dosed in pancreatic cancer
September 30, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/silexion-therapeutics-begins-phase-2-3-sil204-trial-with-first-patient-dosed-in-pancreatic-cancer/ar-AA2dhSLv
Silexion Doses First Patient In Phase 2/3 SIL204 Trial For Pancreatic Cancer
September 30, 2026  |  rttnews.comhttps://www.rttnews.com/3695363/silexion-doses-first-patient-in-phase-2-3-sil204-trial-for-pancreatic-cancer.aspx
See More Silexion Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silexion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silexion Therapeutics and other key companies, straight to your email.

About Silexion Therapeutics

Silexion Therapeutics (NASDAQ:SLXN) Ltd. (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on developing targeted treatments for cancer, with an emphasis on tumors driven by mutations in the KRAS gene. The company’s primary focus is pancreatic cancer, a disease in which KRAS mutations are common and historically difficult to treat.

Silexion is developing RNA-based therapies designed to suppress cancer-promoting KRAS activity. Its pipeline has included siG12D-LODER, a locally administered therapy intended to deliver small interfering RNA against the KRAS G12D mutation, and SIL-204, a next-generation formulation designed to support broader or systemic delivery of KRAS-targeting treatment.

The company originated in Israel and has conducted its research and clinical development activities through Israeli and international collaborations and clinical programs. Silexion’s work remains focused on advancing its KRAS-targeted platform toward additional clinical studies and potential treatments for patients with difficult-to-treat solid tumors.

View Silexion Therapeutics Profile
Earnings Tools